CervoMed报告季度损失和收入比预期的要大,远远低于估计,截至2026年3月16日,短期利息上升,股票价格为4.31美元。 CervoMed reported a larger-than-expected quarterly loss and revenue far below estimates, with rising short interest and a stock price of $4.31 as of March 16, 2026.

CervoMed Inc.(CRVO)报告,截至2026年3月13日,季度损失每股0.88美元,损失估计数为0.09美元,收入为10 000美元,远远低于预期的840 000美元。 CervoMed Inc. (CRVO) reported a quarterly loss of $0.88 per share, missing estimates by $0.09, and revenue of $10,000, far below the expected $840,000, as of March 13, 2026. 到2月27日,短期利息增长了17.9%,达到296 365股,其中5.0%的股票短售。 Short interest rose 17.9% to 296,365 shares by February 27, with 5.0% of shares sold short. 3月16日,库存以4.31美元关闭,增加了0.06美元,数额低于平均数量。 The stock closed at $4.31 on March 16, up $0.06, with below-average volume. 该公司是一家总部设在波士顿的生物技术公司,成立于2010年,正在研制神经退化性疾病的流行性肾上腺炎模型和临床前试验中的EIP200。 The company, a Boston-based biotech founded in 2010, is developing neflamapimod for neurodegenerative diseases and EIP200 in preclinical trials. 分析家预计,每股全年损失1.88美元,评级从“买”到“出售”不等。 Analysts expect a full-year loss of $1.88 per share, with ratings ranging from "buy" to "sell." 机构投资者持有25.15%的股份。 Institutional investors own 25.15% of shares.